Biofrontera (BFRI) AI Stock Analysis

• Market Cap: $10.24M
• Dividend Yield: N/A
• Average Volume (3M): 290.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: 11.20%
• EPS Growth: 63.16%
• Country: US
• Employees: 92
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.57
• Shares Outstanding: 10,668,442
• 10 Day Avg. Volume: 136,303
• 30 Day Avg. Volume: 290,561
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 0.11
• Enterprise Value/Gross Profit: 0.18
• Enterprise Value/Ebitda: -0.29
• 1Y Price Target: $6.50
• Price Target Upside: 577.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $1.00 ▲(4.17% Upside)

Biofrontera's overall score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. Technical analysis shows some positive momentum, but valuation concerns persist due to negative earnings. The earnings call provided a positive outlook with strategic improvements, though financial risks remain significant.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand for Biofrontera's products, enhancing its market position and supporting long-term financial stability.

Strategic Independence

Achieving strategic independence reduces costs and enhances operational flexibility, allowing Biofrontera to better control its financial and strategic direction.

Patent Extension

The patent extension secures long-term revenue streams and strengthens Biofrontera's competitive advantage in the dermatological market.

Negative Factors

Profitability Challenges

Ongoing profitability challenges can hinder Biofrontera's ability to reinvest in growth and innovation, potentially affecting its competitive position.

High SG&A Expenses

Rising SG&A expenses, driven by legal costs, can strain financial resources and reduce operational efficiency, impacting long-term profitability.

Cash Flow Challenges

Negative cash flow highlights the company's reliance on external funding, which can limit financial flexibility and increase risk during economic downturns.

Biofrontera Business Overview & Revenue Model

Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

How the Company Makes Money

Biofrontera Inc. generates revenue through the sales of its dermatological products, primarily Ameluz, in various markets. The company earns money by selling Ameluz to dermatologists, clinics, and hospitals, where it is used for treating actinic keratoses through photodynamic therapy. Biofrontera also sells or leases its BF-RhodoLED lamps, which are used in conjunction with Ameluz to perform the therapy. The company's revenue is further supported by partnerships and distribution agreements, which help expand its market reach. Biofrontera may also engage in licensing agreements or co-development partnerships that contribute to its financial growth.

Biofrontera Financial Statement Overview

Summary

Biofrontera shows revenue growth but struggles with profitability and cash flow, evidenced by negative net income and operating cash flows. High leverage and dependence on financing pose risks to financial stability.

Income Statement

Biofrontera's revenue grew by 9.49% from 2023 to 2024, indicating a positive growth trend. However, the company remains unprofitable with consistently negative net income and EBIT margins, reflecting ongoing operational challenges.

Balance Sheet

The company's high debt-to-equity ratio, driven by substantial liabilities, raises concerns about financial stability. Despite a positive equity ratio, the negative return on equity highlights profitability issues.

Cash Flow

While operating cash flow improved in 2024, it remains negative, indicating ongoing cash flow challenges. The substantial financing cash flow suggests reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.18M	37.30M	34.07M	28.67M	24.10M	18.85M
Gross Profit	24.16M	18.70M	16.63M	13.49M	11.36M	9.78M
EBITDA	-15.41M	-14.44M	-18.45M	934.00K	-36.76M	-7.49M
Net Income	-16.59M	-17.76M	-20.13M	-640.00K	-37.71M	-10.99M
Balance Sheet
Total Assets	20.14M	22.10M	27.93M	50.88M	53.22M	24.14M
Cash, Cash Equivalents and Short-Term Investments	7.24M	5.91M	1.42M	27.76M	24.55M	8.08M
Total Debt	5.00M	4.92M	5.40M	1.35M	0.00	0.00
Total Liabilities	24.81M	17.67M	23.14M	27.00M	41.88M	18.31M
Stockholders Equity	-4.67M	4.43M	4.79M	23.88M	11.34M	5.83M
Cash Flow
Free Cash Flow	-9.34M	-10.28M	-24.90M	-16.24M	-26.73M	-12.37M
Operating Cash Flow	-9.39M	-10.27M	-24.89M	-16.20M	-26.71M	-12.37M
Investing Cash Flow	-5.00K	-3.00K	619.00K	-5.16M	-11.00K	0.00
Financing Cash Flow	12.25M	14.84M	8.41M	14.02M	43.19M	13.19M

Biofrontera Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BFRI, the sentiment is Positive. The current price of 0.96 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.93, and above the 200-day MA of 0.89, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.21 is Neutral, neither overbought nor oversold. The STOCH value of 54.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BFRI.

Biofrontera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COSM	53 Neutral	33.49M	-1.09	-65.96%	―	―	―
BFRI	52 Neutral	$10.24M	―	-531.54%	―	11.20%	63.16%
AYTU	50 Neutral	17.25M	-0.62	-71.51%	―	-18.05%	33.87%
CPHI	46 Neutral	6.11M	-1.24	-61.13%	―	-29.64%	73.63%
SBFM	46 Neutral	6.65M	-0.56	-24.55%	―	19.22%	98.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Biofrontera Corporate Events

Biofrontera Appoints New Chief Commercial Officer

On August 11, 2025, Biofrontera Inc. announced the appointment of George Jones as Chief Commercial Officer, effective August 25, 2025. Jones, with over 25 years of experience in the pharmaceutical and biotech sectors, will oversee the company’s commercial functions. This appointment comes as Biofrontera strengthens its management following the acquisition of all rights and assets related to Ameluz® and RhodoLED® for the U.S. market from Biofrontera AG. The acquisition is expected to bring the company closer to cash break-even by reducing royalty payments. Jones’ extensive experience in commercial leadership is anticipated to accelerate Biofrontera’s growth and enhance its market access strategies.

The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.

Biofrontera Finalizes Acquisition of U.S. Ameluz Rights

On June 30, 2025, Biofrontera Inc. finalized an agreement with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®. This strategic transaction involves a royalty payment structure and grants Biofrontera AG a 10% equity stake in Biofrontera Inc. through Series D Convertible Preferred Stock. Additionally, a private placement of Series C Preferred Stock was initiated on June 27, 2025, to fund the acquisition, with proceeds expected to reach $11 million. This move is expected to enhance Biofrontera Inc.’s market presence in the U.S. and streamline its operations by consolidating rights to its key products.

The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.